Cheryl A. Sadowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cheryl A. Sadowski has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Adriana Chubaty
University of Alberta Hospital, Edmonton, Alberta, Canada
1 shared publicationAdrienne J Lindblad
ADRIENNE J LINDBLAD BSP ACPR PharmD, at time of writing, PharmD Student, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada now, Clinical Coordinator, David Thompson Health Region, Red Deer, Alberta, Canada
1 shared publicationAnita G. Carrie
Canadian Agency for Drugs and Technologies in Health (CADTH), Edmonton, Alberta T5J 3G1 , Canada
1 shared publication- Anita G. Carrie
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
1 shared publication Christine Hughes
Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta. Contact . Ms. Lang is a 3rd-y ear pharmacy student at the University of Alberta and completed this review under the supervision of Drs. Sadowski and Hughes during a summer research project
1 shared publication- Colleen Metge
University of Manitoba, Winnipeg, Manitoba, Canada
1 shared publication
Latest Publications
- 1 May 2011
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 144 (3) , 132-141
Vaccinations in Older Adults: Focus on Pneumococcal, Influenza and Herpes zoster infections
Pneumococcal, influenza and herpes zoster infections cause significant morbidity and mortality in the aging population. Effective vaccines are available in Canada to prevent and minimize illnesses caused by these infections. The purpose of this review is to provide an overview of the epidemiology of pneumococcal, influenza and herpes zoster infections in older adults, as well as available vaccines and recommended immunization schedules. In addition, the benefits of these vaccines on patient outcomes and the role of pharmacists in improving immunization rates are highlighted. A literature review was conducted to examine the clinical outcomes related to the use of pneumococcal, influenza and herpes zoster vaccines in adults 65 years and older. All 3 vaccines are beneficial in reducing complications of these infections and are well tolerated in older adults. Studies have shown that the uptake of these vaccines remains suboptimal and the burden of illness caused by these infections continues to affect the quality of life of older adults. Pharmacists are well positioned to screen seniors for vaccine indications during routine assessments, as well as provide education to improve patient awareness, vaccine uptake and health outcomes in older adults.
- 1 May 2011
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 144 (3) , 132-141
Vaccinations in Older Adults: Focus on Pneumococcal, Influenza and Herpes zoster infections
Pneumococcal, influenza and herpes zoster infections cause significant morbidity and mortality in the aging population. Effective vaccines are available in Canada to prevent and minimize illnesses caused by these infections. The purpose of this review is to provide an overview of the epidemiology of pneumococcal, influenza and herpes zoster infections in older adults, as well as available vaccines and recommended immunization schedules. In addition, the benefits of these vaccines on patient outcomes and the role of pharmacists in improving immunization rates are highlighted. A literature review was conducted to examine the clinical outcomes related to the use of pneumococcal, influenza and herpes zoster vaccines in adults 65 years and older. All 3 vaccines are beneficial in reducing complications of these infections and are well tolerated in older adults. Studies have shown that the uptake of these vaccines remains suboptimal and the burden of illness caused by these infections continues to affect the quality of life of older adults. Pharmacists are well positioned to screen seniors for vaccine indications during routine assessments, as well as provide education to improve patient awareness, vaccine uptake and health outcomes in older adults.
- 28 February 2011
- Published by Canadian Society of Healthcare-Systems Pharmacy in The Canadian Journal of Hospital Pharmacy
- Vol. 64 (1) , 36-41
Use of Oral Bisphosphonates by Older Adults with Fractures and Impaired Renal Function
Use of Oral Bisphosphonates by Older Adults with Fractures and Impaired Renal Function
- 28 February 2011
- Published by Canadian Society of Healthcare-Systems Pharmacy in The Canadian Journal of Hospital Pharmacy
- Vol. 64 (1) , 36-41
Use of Oral Bisphosphonates by Older Adults with Fractures and Impaired Renal Function
Use of Oral Bisphosphonates by Older Adults with Fractures and Impaired Renal Function
- 19 November 2010
- Published by Cambridge University Press (CUP) in Reviews in Clinical Gerontology
- Vol. 21 (1) , 55-66
Providing health information to older adults
Summary Providing information to older adults is essential for informed decision-making and good health. Because there are significant deficits in providing information verbally, health professionals must use written information as well. Most studies have focused on the content and literacy of documents. However, the legibility and formatting are critically important for older adults, who are more likely to suffer with visual impairment. Providing written information that is tested for appropriate reading level and for presentation is necessary to ensure that older adults can use the information given. There are a number of tools available that test these aspects of written information, but not one tool that is universally accepted. Further research regarding the design and presentation of written information for older adults is necessary.
- 19 November 2010
- Published by Cambridge University Press (CUP) in Reviews in Clinical Gerontology
- Vol. 21 (1) , 55-66
Providing health information to older adults
Summary Providing information to older adults is essential for informed decision-making and good health. Because there are significant deficits in providing information verbally, health professionals must use written information as well. Most studies have focused on the content and literacy of documents. However, the legibility and formatting are critically important for older adults, who are more likely to suffer with visual impairment. Providing written information that is tested for appropriate reading level and for presentation is necessary to ensure that older adults can use the information given. There are a number of tools available that test these aspects of written information, but not one tool that is universally accepted. Further research regarding the design and presentation of written information for older adults is necessary.
- Open Access
- 30 May 2009
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 38 (4) , 441-447
Typeface legibility of patient information leaflets intended for community-dwelling seniors
Background: there are guidelines available from a number of countries and organisations regarding the design of written information, as appropriate design is essential for effective communication. The design of leaflets should be evaluated, as written information that does not adhere to guidelines may not be effective for seniors. Objective: to use current typeface guidelines to describe the design of health information leaflets. Design: this was a cross-sectional study of leaflets from pharmacies and seniors’ clinics. Setting: community pharmacies, seniors’ clinics in Edmonton, Canada. Methods: health information leaflets and hydrochlorthiazide information sheets were collected. The body of each was evaluated, based on guidelines (from Canada, UK and USA). Adherence to recommendations was assessed descriptively. Results: a total of 388 unique leaflets and 10 hydrochlorthiazide sheets were collected from 21 pharmacies and 3 clinics. Most leaflets were produced by pharmaceutical companies (42.8%) and contained disease information (43.8%). Only one-third of all leaflets used the minimum recommended point size (12 point), 18.6% followed American guidelines for line spacing (1.5 lines), but 77.1% had appropriate contrast. Conclusions: although guidelines are available, most leaflets did not meet recommendations. Improvements in the leaflet design should be considered to aid seniors in the uptake of information.
- 30 May 2009
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 38 (4) , 441-447
Open AccessTypeface legibility of patient information leaflets intended for community-dwelling seniors
Background: there are guidelines available from a number of countries and organisations regarding the design of written information, as appropriate design is essential for effective communication. The design of leaflets should be evaluated, as written information that does not adhere to guidelines may not be effective for seniors. Objective: to use current typeface guidelines to describe the design of health information leaflets. Design: this was a cross-sectional study of leaflets from pharmacies and seniors’ clinics. Setting: community pharmacies, seniors’ clinics in Edmonton, Canada. Methods: health information leaflets and hydrochlorthiazide information sheets were collected. The body of each was evaluated, based on guidelines (from Canada, UK and USA). Adherence to recommendations was assessed descriptively. Results: a total of 388 unique leaflets and 10 hydrochlorthiazide sheets were collected from 21 pharmacies and 3 clinics. Most leaflets were produced by pharmaceutical companies (42.8%) and contained disease information (43.8%). Only one-third of all leaflets used the minimum recommended point size (12 point), 18.6% followed American guidelines for line spacing (1.5 lines), but 77.1% had appropriate contrast. Conclusions: although guidelines are available, most leaflets did not meet recommendations. Improvements in the leaflet design should be considered to aid seniors in the uptake of information.
- 29 May 2009
- Vol. 16 (2) , e322-30
Access and intensity of use of prescription analgesics among older Manitobans.
Under-treatment of pain is frequently reported, especially among seniors, with chronic non-cancer pain most likely to be under-treated. Legislation regarding the prescribing/dispensing of opioid analgesics (including multiple prescription programs [MPP]) may impede access to needed analgesics. To describe access and intensity of use of analgesics among older Manitobans by health region. A cross-sectional study of non-Aboriginal non-institutionalized Manitoba residents over 65 years of age during April 1, 2002 to March 31, 2003 was conducted using the Pharmaceutical Claims data and the Cancer Registry from the province of Manitoba. Access to analgesics (users/1000/Yr) and intensity of use (using defined daily dose [DDD] methodology) were calculated for non-opioid analgesics, opioids, and multiple-prescription-program opioids [MPP-opioids]. Usage was categorized by age, gender, and stratified by cancer diagnosis. Age-sex standardized rates of prevalence and intensity are reported for the eleven health regions of Manitoba. Thirty-four percent of older Manitobans accessed analgesics during the study period. Female gender, increasing age, and a cancer diagnosis were associated with greater access and intensity of use of all classes of analgesics. Age-sex standardized access and intensity measures revealed the highest overall analgesic use in the most rural / remote regions of the province. However, these same regions had the lowest use of opioids, and MPP-opioids among residents lacking a cancer diagnosis. This population-based study of analgesic use suggests that there may be variations in use of opioids and other analgesics depending on an urban or rural residence. The impact of programs such as the MPP program requires further study to describe its impact on analgesic use.
- 29 May 2009
- Vol. 16 (2) , e322-30
Access and intensity of use of prescription analgesics among older Manitobans.
Under-treatment of pain is frequently reported, especially among seniors, with chronic non-cancer pain most likely to be under-treated. Legislation regarding the prescribing/dispensing of opioid analgesics (including multiple prescription programs [MPP]) may impede access to needed analgesics. To describe access and intensity of use of analgesics among older Manitobans by health region. A cross-sectional study of non-Aboriginal non-institutionalized Manitoba residents over 65 years of age during April 1, 2002 to March 31, 2003 was conducted using the Pharmaceutical Claims data and the Cancer Registry from the province of Manitoba. Access to analgesics (users/1000/Yr) and intensity of use (using defined daily dose [DDD] methodology) were calculated for non-opioid analgesics, opioids, and multiple-prescription-program opioids [MPP-opioids]. Usage was categorized by age, gender, and stratified by cancer diagnosis. Age-sex standardized rates of prevalence and intensity are reported for the eleven health regions of Manitoba. Thirty-four percent of older Manitobans accessed analgesics during the study period. Female gender, increasing age, and a cancer diagnosis were associated with greater access and intensity of use of all classes of analgesics. Age-sex standardized access and intensity measures revealed the highest overall analgesic use in the most rural / remote regions of the province. However, these same regions had the lowest use of opioids, and MPP-opioids among residents lacking a cancer diagnosis. This population-based study of analgesic use suggests that there may be variations in use of opioids and other analgesics depending on an urban or rural residence. The impact of programs such as the MPP program requires further study to describe its impact on analgesic use.
- 1 July 2008
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 24 (4) , 213-218
Safety of Proton Pump Inhibitors in Community-Dwelling Older Adults
Objective: To describe proton pump inhibitor (PPI)–related adverse effects in community-dwelling older adults. Data Sources: Articles were identified via PubMed (1966–March 2008) using the terms proton pump inhibitor, adverse drug effects, safety, pneumonia, fractures, Clostridium difficile, and vitamin B12. Clinical trials, meta-analyses, and drug evaluations published in English were selected. Articles excluding patients over 65 years of age or those involving solely institutionalized patients were excluded. Study Selection and Data Extraction: Twelve studies were selected, 10 of which were case–control or population-based studies. Three of 4 studies investigating the association of PPI use with C. difficile infection found a positive association. Many participants in these studies had no history of antibiotic exposure prior to infection. Three studies found a significant relationship between community-acquired pneumonia and PPI therapy, with a possible dose–response relationship. Two studies found an increased risk of fracture with PPI use, with a possible dose–response relationship. Two of 3 included studies found an association between vitamin B12 deficiency and PPI therapy. Data Synthesis: The majority of studies found significant associations between PPI use and the development of C. difficile infection, pneumonia, fractures, and vitamin B12 deficiency, all of which are plausible based on the mechanisms of action of PPIs. With a lack of randomized controlled trials, the underlying causes of these adverse effects remain controversial. Conclusions: Cause and effect between PPI use and C. difficile infection, pneumonia, fractures, and vitamin B12 deficiency has not been established. Well-designed, prospective, randomized studies are required to confirm whether there are risks associated with long-term PPI use. Until the results of such studies become available, PPI use should be reviewed for appropriateness at regular intervals in individual patients, as the consequences of these complications in the elderly could be devastating.
- 1 July 2008
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 24 (4) , 213-218
Safety of Proton Pump Inhibitors in Community-Dwelling Older Adults
Objective: To describe proton pump inhibitor (PPI)–related adverse effects in community-dwelling older adults. Data Sources: Articles were identified via PubMed (1966–March 2008) using the terms proton pump inhibitor, adverse drug effects, safety, pneumonia, fractures, Clostridium difficile, and vitamin B12. Clinical trials, meta-analyses, and drug evaluations published in English were selected. Articles excluding patients over 65 years of age or those involving solely institutionalized patients were excluded. Study Selection and Data Extraction: Twelve studies were selected, 10 of which were case–control or population-based studies. Three of 4 studies investigating the association of PPI use with C. difficile infection found a positive association. Many participants in these studies had no history of antibiotic exposure prior to infection. Three studies found a significant relationship between community-acquired pneumonia and PPI therapy, with a possible dose–response relationship. Two studies found an increased risk of fracture with PPI use, with a possible dose–response relationship. Two of 3 included studies found an association between vitamin B12 deficiency and PPI therapy. Data Synthesis: The majority of studies found significant associations between PPI use and the development of C. difficile infection, pneumonia, fractures, and vitamin B12 deficiency, all of which are plausible based on the mechanisms of action of PPIs. With a lack of randomized controlled trials, the underlying causes of these adverse effects remain controversial. Conclusions: Cause and effect between PPI use and C. difficile infection, pneumonia, fractures, and vitamin B12 deficiency has not been established. Well-designed, prospective, randomized studies are required to confirm whether there are risks associated with long-term PPI use. Until the results of such studies become available, PPI use should be reviewed for appropriateness at regular intervals in individual patients, as the consequences of these complications in the elderly could be devastating.
- Open Access
- 11 May 2008
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 11 (3) , 66-67
Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice, 3rd Edition
Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice, 3rd Edition
- 11 May 2008
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 11 (3) , 66-67
Open AccessPathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice, 3rd Edition
Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice, 3rd Edition